Across the world attitudes towards cannabis are beginning to relax and in no country is this more evident than in Canada. In recent years, the view has shifted from marijuana being a dangerous drug to a viable medicine, and now to an appropriate form of recreation. Although already prescribed for
Healthcare
Should I Buy Weed Stocks?
Global M&A Roundup Nov 24, 2017 – Cavium, Huaxia Life Insurance, DaVita Medical Group, Sun Art Retail
Our previous Canadian Mergers & Acquisitions roundups can be found here. Our previous global M&A roundups can be found here. Target: Cavium Inc Industry: Technology Acquirer: Cavium Inc Target: Marvell Technology Group Size: $6 Billion Consideration: Cash & Stock Sell Side Advisors: JP Morgan, Qatalyst Group Buy Side Advisors: Goldman Sachs Legal Advisors: Skadden Arps On November 20th 2017, Marvell technology group entered into
Canadian M&A Roundup Nov 17, 2017 – Weyburn/Cenovus, CanniMed Therapeutics, Care Investment Trust, General Growth Properties
Our previous Canadian Mergers & Acquisitions roundups can be found here. Our previous global M&A roundups can be found here. Target: Weyburn Unit and Minor Assets, Cenovus Energy Inc. Industry: Energy Acquirer: Whitecap Resources Inc. Target: Weyburn Unit and Minor Assets in southeast Saskatchewan, Cenovus Energy Inc. Size: CAD 940 million Consideration: 100% Cash Source of Funds: Debt, Equity
Global ECM Weekly Monitor Nov 17, 2017 – Alnylam Pharmaceuticals, Norwegian Cruise Line Holdings, Gardner Denver Holdings
Our previous Global ECM Weekly Monitors can be found here. Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY) Announcement Date: November 13, 2017 Gross Offering Amount: USD $700 million Price per share: $125 Lead Banks: Goldman Sachs, JP Morgan, Barclays, Barclays Nature of the issue: Follow-on Equity Offering; General Corporate Purposes Security Issued: Common Stock Overallotment: $105
Global M&A Roundup Nov 10, 2017 – Hengda Real Estate, Mattel, Ortho-Clinical Diagnostics
Our previous Canadian Mergers & Acquisitions roundups can be found here. Our previous global M&A roundups can be found here. Target: Hengda Real Estate Group Industry: Real Estate Acquirer: Multiple buyers Target: Hengda Real Estate Group Size: 9.1 billion Consideration: Cash Sell Side Advisors: Undisclosed Buy Side Advisors: Gram Capital Legal Advisors: Undisclosed On November 6th,
Global M&A Roundup Oct 13, 2017 – eviCore healthcare, Bayer
Our previous Canadian Mergers & Acquisitions roundups can be found here. Our previous global M&A roundups can be found here. Target: eviCore healthcare, LLC Industry: Healthcare, Technology Acquirer: Oz Parent, Inc. Target: eviCore healthcare, LLC Size: $3.6 billion Consideration: 100% Cash Source of Funds: Cash, Debt Sell Side Advisors: JP Morgan, Morgan Stanley Buy Side
Global M&A Roundup Sep 15, 2017 – The New York State Catholic Health Plan, Inc.
Our previous Canadian Mergers & Acquisitions roundups can be found here. Our previous global M&A roundups can be found here. Target: The New York State Catholic Health Plan, Inc. Industry: Healthcare / Financial Institutions - Insurance Acquirer: Centene Corporation (NYSE:CNC) Target: The New York State Catholic Health Plan, Inc. Size: $3.75 billion Consideration: 100% Cash
Global M&A Roundup Sep 1, 2017 – Advisory Board Company, Kite Pharma
Our previous Canadian Mergers & Acquisitions roundups can be found here. Our previous global M&A roundups can be found here. Target: The Advisory Board Company (NasdaqGS:ABCO) Industry: Healthcare - Research and Consulting Services Acquirer: OptumInsight, Inc. Target: The Advisory Board Company Size: $2.9 billion Consideration: 92% Cash, 8% Equity Source of Funds: Cash, Common Stock
Weekly Movers Sep 1, 2017 – Polaris Materials, Prometic Life Sciences, Toromont, Painted Pony
Top TSX Weekly Gainers Polaris Materials Corp (TSX:PLS, Chg:183.3%) Industry: Basic Materials Vulcan Materials, a $16bn construction aggregates and concrete producer agreed to acquire PLS for $2.79/share in cash, valuing PLS equity at about $252mm. PLS closed last Friday at $0.96. Prometic Life Sciences Inc (TSX:PLI, Chg:25.8%) Industry: Healthcare On August 29, 2017 PLI announced that